NASDAQ$EWTX
Edgewise Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year of 2021 and recent business highlights.
Edgewise Therapeutics reported positive topline results from the EDG-5506 Phase 1b clinical trial in adults with Becker muscular dystrophy (BMD). Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) are planned to start in 2022. Cash, cash equivalents and marketable securities were $281 million as of December 31, 2021.
- Announced positive topline results from the EDG-5506 Phase 1b clinical trial in adults with Becker muscular dystrophy (BMD).
- Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) planned to start in 2022.
- Initiated treatment in the ARCH open label study evaluating EDG-5506 in adult males with BMD.
- Cash, cash equivalents and marketable securities were $281 million as of December 31, 2021.
Headline financials
Revenue & EPS history
Edgewise Therapeutics · Revenue · Quarterly
$0
Forward guidance
The Company anticipates initiating Phase 2 trials in individuals with BMD in the first half of 2022 and DMD in the second half of 2022. The Company anticipates interim data from the ARCH trial in the first half of 2022.
Tailwinds
- Initiating Phase 2 trials in individuals with BMD in the first half of 2022
- Initiating Phase 2 trials in individuals with DMD in the second half of 2022
- Advancing the EDG-002 program, focused on identifying cardiac muscle modulators
- Advancing EDG-5440, a next generation myosin ATPase modulator designed to target skeletal muscle
- Anticipates interim data from the ARCH trial in the first half of 2022
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+16.0%
Q2 2022
Best reaction
-12.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.7% | -4.3% | +2.4% | |
| Q3 2025 | -1.7% | +23.7% | +35.8% | |
| Q2 2025 | -4.1% | -0.9% | +15.2% | |
| Q1 2025 | +2.4% | +1.0% | +5.8% | |
| Q4 2024 | -2.4% | +7.0% | -40.7% | |
| Q3 2024 | -0.7% | -3.9% | -11.0% | |
| Q1 2024 | -12.3% | -16.5% | -15.5% | |
| Q4 2023 | -1.3% | -3.7% | -7.1% | |
| Q3 2023 | -10.7% | +5.5% | +13.0% | |
| Q2 2023 | +3.4% | +12.5% | -3.4% | |
| Q1 2023 | -6.5% | -5.5% | -2.8% | |
| Q4 2022 | -3.0% | -2.8% | -30.3% | |
| Q3 2022 | +1.8% | +2.1% | -5.7% | |
| Q2 2022 | +16.0% | +6.8% | +17.1% | |
| Q1 2022 | +1.6% | -0.8% | -18.9% | |
| Q4 2021 | +13.0% | -2.5% | -19.3% | |
| Q3 2021 | -1.8% | -3.4% | -3.1% | |
| Q2 2021 | -5.6% | -10.6% | -7.9% | |
| Q1 2021 | +5.2% | +4.7% | -1.6% | |
| Q4 2020 | +5.2% | +4.7% | -1.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro